N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
about
Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine developmentProximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopesStructure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data setStructure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopyAnti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypesThe influence of N-linked glycans on the molecular dynamics of the HIV-1 gp120 V3 loop.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Structural analysis of the HIV-1 gp120 V3 loop: application to the HIV-Haiti isolates.Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.Different tempo and anatomic location of dual-tropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection.CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodiesThe V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression.Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4.Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection.Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infectionsVariable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaquesHuman immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulationHIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRF01_AE and CRF02_AG [corrected].Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes.HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodiesUnique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formationComparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins
P2860
Q21558777-0A0E9B22-CF84-4680-89D5-FD8FAEC94F8DQ24645308-D894CD9C-817A-468C-A977-0CA978B40E7AQ27650903-218A4E96-AC18-4038-A1E0-45CCD95B579AQ28654490-F20357E2-1B90-47F4-BB59-275896808E6BQ28752503-3FEC0073-8EFF-48F3-BFA1-9715E76D9659Q30356350-16A9EB23-1050-4462-A0A1-297ADB015406Q30379200-544749CB-154C-42E1-9D57-36C39E55D3E4Q31112947-6D10B0E5-415A-44C8-851B-BB46C56273A1Q33518005-BEEB1150-28C4-4435-B1FE-744FFFE86415Q33558676-F299FF39-FB56-49BF-865B-5B2751B394F0Q33743734-D272E2E8-D7FA-4B74-85AB-A606A76F941EQ33883936-A9255B93-F172-4348-B2DA-5AE68F30B9C7Q33967039-9DA88AD1-0754-4177-95FF-D3C6099444D3Q33980469-71FE719D-B553-47D1-BC18-EBC75F6BAE3EQ33984371-1E2C1A85-352E-47DF-A8F2-CD75D077BD66Q34008699-24AE6457-E048-4543-AECE-D6608B4D1BFAQ34016211-D1EF5EAA-7684-4447-8FDD-D8E70C7A1984Q34034659-6B7E9306-1E52-4225-A016-6BC7CE24C7BBQ34042642-2EAF6E32-F9F3-49E5-A26F-3D5BE1589752Q34178201-A8EC67A7-C2DE-4BA1-A6D2-934392C5FF14Q34301728-37726133-E786-467E-BAB8-EB2C59D6BC21Q34301803-2F051F3D-0257-4404-8DAA-4C80D9AB14B6Q34478071-1FA557CC-3600-48AE-9D63-B0BAC933EA27Q34485260-D54B2FD2-7A1D-4A50-901A-3A368FE48028Q34533041-0BC71051-3F3D-40FB-86BD-AA1EB41C027DQ34551010-21585C09-77E0-4DDC-AB37-76363E35FE53Q34555891-C9525DFD-A571-4969-A119-60A41A073B09Q34694812-4AC3F684-485E-40B9-8EB4-78020D1CF0EFQ34716813-23E637B9-B0E8-4559-B6C5-FE2E6DE0EB3DQ34717733-3A366E7D-A42F-4487-99EA-3F41C40ECED8Q34987062-D5CBDE8E-8C0A-4E47-ABA5-40D04041E8E4Q34990575-B4DEC2CC-1ECB-4631-ACE8-CEEC1854FDA8Q35665921-324D2E52-9FB8-47FB-A7B7-9D76A696D963Q35785244-60518311-ED28-4E97-82AB-1C791E539F3AQ35817106-E6B5B8CF-B57F-4126-ABBB-12D1155D5063Q35857254-64B08F99-BA74-4ED1-B31E-BCE46DA471EAQ35857683-28EF24F7-03C7-4A7B-B247-9A6758B78D62Q35893538-8D8EF172-EBD5-4E03-8213-8941E939D647Q35914280-CD7E1153-A90E-4EF8-B3C1-DF5580BF8CF8Q35985896-E4CDC0A5-08C6-4F40-9115-FDAA98879DA4
P2860
N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
N-linked glycosylation of the ...... p120 and anti-gp41 antibodies.
@en
N-linked glycosylation of the ...... p120 and anti-gp41 antibodies.
@nl
type
label
N-linked glycosylation of the ...... p120 and anti-gp41 antibodies.
@en
N-linked glycosylation of the ...... p120 and anti-gp41 antibodies.
@nl
prefLabel
N-linked glycosylation of the ...... p120 and anti-gp41 antibodies.
@en
N-linked glycosylation of the ...... p120 and anti-gp41 antibodies.
@nl
P2093
P2860
P1433
P1476
N-linked glycosylation of the ...... p120 and anti-gp41 antibodies.
@en
P2093
Cheryl Saunders
Leonidas Stamatatos
Mike Hensel
Ruth A McCaffrey
P2860
P304
P356
10.1128/JVI.78.7.3279-3295.2004
P407
P577
2004-04-01T00:00:00Z